Healthcare AI company AIDOT has drawn attention from the medical community by introducing Korea’s first on-device AI cervical cancer diagnostic device, capable of performing immediate analysis on-site without relying on cloud or server infrastructure.

This device is recognized as an innovative solution for patient data privacy and security, as hospital data does not need to be transferred externally. All AI processing is conducted within the device itself, meaning the patient’s original images are never sent to external servers.

Key advantages of the device include:

• No need for data transfer

• Enhanced security

• Instant analysis independent of network conditions

Cerviray AI is also the first AI solution in Korea to classify and detect four types of cervical lesions—Normal, CIN1, CIN2·3, and Cancer—making it the only Ministry of Food and Drug Safety (MFDS) Class III approved device with this capability. Beyond detecting the presence of lesions, the system can accurately pinpoint their locations, significantly improving both diagnostic accuracy and clinical utility.

An AIDOT representative emphasized,
“With this functionality, Cerviray AI is the only device in Korea that has received MFDS Class III approval. While other companies may attempt to replicate our solution, ours remains the only authorized product capable of marking cervical lesions using AI.”

The company further highlighted that Cerviray AI is the only on-device AI cervical cancer diagnostic device officially approved in Korea, demonstrating both technological reliability and originality within a highly regulated environment, and establishing differentiated competitiveness in the domestic AI healthcare market.

To maximize on-site usability, AIDOT also unveiled a battery-replaceable upgraded model, enabling stable operation in hospitals, public health centers, and international medical support sites where long-duration use is required.

Korea Economic TV / November 24, 2025 / Deputy Editor Jaejun Yang